Allos Therapeutics, Inc. (ALTH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Allos Therapeutics, Inc. (ALTH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	9/6/2006 1:40:47 AM
	of 226

09:44 am Allos Therapeutics: Needham & Co upgrades Buy to Strong Buy. Target $5 to $9. Needham upgrades ALTH to Strong Buy from Buy and raises their tgt to $9 from $5 based on a) revision of projected revs from Efaproxyn, b) inclusion of PDX in their product model, and c) upcoming news flow that they believe will drive the stock. With two unpartnered products in pivotal Phase 3 (EFAPROXYN) and Phase 2 (PDX) trials, the firm believes ALTH stock (technology value $171 mln) represents a compelling investment opportunity.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next